These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 16585161)

  • 41. Essential, non-redundant roles of B-Raf and Raf-1 in Ras-driven skin tumorigenesis.
    Kern F; Doma E; Rupp C; Niault T; Baccarini M
    Oncogene; 2013 May; 32(19):2483-92. PubMed ID: 22733131
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Loss of RAF kinase inhibitor protein is a somatic event in the pathogenesis of therapy-related acute myeloid leukemias with C-RAF germline mutations.
    Zebisch A; Haller M; Hiden K; Goebel T; Hoefler G; Troppmair J; Sill H
    Leukemia; 2009 Jun; 23(6):1049-53. PubMed ID: 19357705
    [TBL] [Abstract][Full Text] [Related]  

  • 43. DA-Raf, a dominant-negative antagonist of the Ras-ERK pathway, is a putative tumor suppressor.
    Kanno E; Kawasaki O; Takahashi K; Takano K; Endo T
    Exp Cell Res; 2018 Jan; 362(1):111-120. PubMed ID: 29129563
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Oncogenic FAM131B-BRAF fusion resulting from 7q34 deletion comprises an alternative mechanism of MAPK pathway activation in pilocytic astrocytoma.
    Cin H; Meyer C; Herr R; Janzarik WG; Lambert S; Jones DT; Jacob K; Benner A; Witt H; Remke M; Bender S; Falkenstein F; Van Anh TN; Olbrich H; von Deimling A; Pekrun A; Kulozik AE; Gnekow A; Scheurlen W; Witt O; Omran H; Jabado N; Collins VP; Brummer T; Marschalek R; Lichter P; Korshunov A; Pfister SM
    Acta Neuropathol; 2011 Jun; 121(6):763-74. PubMed ID: 21424530
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Lack of constitutive activation of MAP kinase pathway in human acute myeloid leukemia cells with N-Ras mutation.
    Iida M; Towatari M; Nakao A; Iida H; Kiyoi H; Nakano Y; Tanimoto M; Saito H; Naoe T
    Leukemia; 1999 Apr; 13(4):585-9. PubMed ID: 10214865
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Absence of classical MAP kinase pathway signalling in Merkel cell carcinoma.
    Houben R; Michel B; Vetter-Kauczok CS; Pföhler C; Laetsch B; Wolter MD; Leonard JH; Trefzer U; Ugurel S; Schrama D; Becker JC
    J Invest Dermatol; 2006 May; 126(5):1135-42. PubMed ID: 16498399
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Raf proteins and cancer: B-Raf is identified as a mutational target.
    Mercer KE; Pritchard CA
    Biochim Biophys Acta; 2003 Jun; 1653(1):25-40. PubMed ID: 12781369
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mutation analysis of B-RAF gene in human gliomas.
    Basto D; Trovisco V; Lopes JM; Martins A; Pardal F; Soares P; Reis RM
    Acta Neuropathol; 2005 Feb; 109(2):207-10. PubMed ID: 15791479
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A ΔRaf1-ER-inducible oncogenic zebrafish liver cell model identifies hepatocellular carcinoma signatures.
    He S; Krens SG; Zhan H; Gong Z; Hogendoorn PC; Spaink HP; Snaar-Jagalska BE
    J Pathol; 2011 Sep; 225(1):19-28. PubMed ID: 21744342
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mixed-lineage-leukemia (MLL) fusion protein collaborates with Ras to induce acute leukemia through aberrant Hox expression and Raf activation.
    Ono R; Kumagai H; Nakajima H; Hishiya A; Taki T; Horikawa K; Takatsu K; Satoh T; Hayashi Y; Kitamura T; Nosaka T
    Leukemia; 2009 Dec; 23(12):2197-209. PubMed ID: 19710696
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sequencing analysis of BRAF mutations in human cancers.
    Wooster R; Futreal AP; Stratton MR
    Methods Enzymol; 2006; 407():218-24. PubMed ID: 16757326
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of feedback phosphorylation and Raf heterodimerization on normal and mutant B-Raf signaling.
    Ritt DA; Monson DM; Specht SI; Morrison DK
    Mol Cell Biol; 2010 Feb; 30(3):806-19. PubMed ID: 19933846
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Identification of Raf-1 S471 as a novel phosphorylation site critical for Raf-1 and B-Raf kinase activities and for MEK binding.
    Zhu J; Balan V; Bronisz A; Balan K; Sun H; Leicht DT; Luo Z; Qin J; Avruch J; Tzivion G
    Mol Biol Cell; 2005 Oct; 16(10):4733-44. PubMed ID: 16093354
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Alternative effects of RAS and RAF oncogenes on the proliferation and apoptosis of factor-dependent FDC-P1 cells.
    McGlynn AP; Padua RA; Burnett AK; Darley RL
    Leuk Res; 2000 Jan; 24(1):47-54. PubMed ID: 10634645
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mutations of the BRAF gene in human cancer.
    Davies H; Bignell GR; Cox C; Stephens P; Edkins S; Clegg S; Teague J; Woffendin H; Garnett MJ; Bottomley W; Davis N; Dicks E; Ewing R; Floyd Y; Gray K; Hall S; Hawes R; Hughes J; Kosmidou V; Menzies A; Mould C; Parker A; Stevens C; Watt S; Hooper S; Wilson R; Jayatilake H; Gusterson BA; Cooper C; Shipley J; Hargrave D; Pritchard-Jones K; Maitland N; Chenevix-Trench G; Riggins GJ; Bigner DD; Palmieri G; Cossu A; Flanagan A; Nicholson A; Ho JW; Leung SY; Yuen ST; Weber BL; Seigler HF; Darrow TL; Paterson H; Marais R; Marshall CJ; Wooster R; Stratton MR; Futreal PA
    Nature; 2002 Jun; 417(6892):949-54. PubMed ID: 12068308
    [TBL] [Abstract][Full Text] [Related]  

  • 56. B-Raf deficiency impairs tumor initiation and progression in a murine breast cancer model.
    Köhler M; Ehrenfeld S; Halbach S; Lauinger M; Burk U; Reischmann N; Cheng S; Spohr C; Uhl FM; Köhler N; Ringwald K; Braun S; Peters C; Zeiser R; Reinheckel T; Brummer T
    Oncogene; 2019 Feb; 38(8):1324-1339. PubMed ID: 30659267
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Functional characterization of a BRAF insertion mutant associated with pilocytic astrocytoma.
    Eisenhardt AE; Olbrich H; Röring M; Janzarik W; Anh TN; Cin H; Remke M; Witt H; Korshunov A; Pfister SM; Omran H; Brummer T
    Int J Cancer; 2011 Nov; 129(9):2297-303. PubMed ID: 21190184
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Absence of point mutations in a functionally important part of the extracellular domain of the c-kit proto-oncogene in a series of patients with acute myeloid leukemia (AML).
    Arland M; Fiedler W; Samalecos A; Hossfeld DK
    Leukemia; 1994 Mar; 8(3):498-501. PubMed ID: 8127154
    [TBL] [Abstract][Full Text] [Related]  

  • 59. V599EB-RAF is an oncogene in melanocytes.
    Wellbrock C; Ogilvie L; Hedley D; Karasarides M; Martin J; Niculescu-Duvaz D; Springer CJ; Marais R
    Cancer Res; 2004 Apr; 64(7):2338-42. PubMed ID: 15059882
    [TBL] [Abstract][Full Text] [Related]  

  • 60. RACK1 regulates Ki-Ras-mediated signaling and morphological transformation of NIH 3T3 cells.
    Bjørndal B; Myklebust LM; Rosendal KR; Myromslien FD; Lorens JB; Nolan G; Bruland O; Lillehaug JR
    Int J Cancer; 2007 Mar; 120(5):961-9. PubMed ID: 17149700
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.